Effect of Decitabine on Regulatory T Cells Relative Content in Peripheral Blood and Bone Marrow of Patients with Myelodysplastic Syndrome/Acute Myeloid Leukemia.
10.19746/j.cnki.issn.1009-2137.2022.01.007
- Author:
Rui HU
1
;
Yuan GAO
2
;
Yan WEN
3
;
Kun WU
2
;
Ci DUAN
2
;
Yun ZENG
2
;
Ming-Xia SHI
4
Author Information
1. Department of Hematology, First Affiliated Hospital of Kunming Medical University, Hematology Research Center of Yunnan Province, Kunming 650032, Yunnan Province, China,Department of Hematology, The First People's Hospital of Yunnan Province, Kunming 650100, Yunnan Province, China.
2. Department of Hematology, First Affiliated Hospital of Kunming Medical University, Hematology Research Center of Yunnan Province, Kunming 650032, Yunnan Province, China.
3. Department of Hematology, The First People's Hospital of Yunnan Province, Kunming 650100, Yunnan Province, China.
4. Department of Hematology, First Affiliated Hospital of Kunming Medical University, Hematology Research Center of Yunnan Province, Kunming 650032, Yunnan Province, China,E-mail: shmxia2002@sina.com.
- Publication Type:Journal Article
- Keywords:
acute myeloid leukemia;
decitabine;
myelodysplastic syndrome;
regulatory T cell;
tumor immunity
- MeSH:
Antineoplastic Combined Chemotherapy Protocols;
Bone Marrow;
Decitabine/therapeutic use*;
Humans;
Leukemia, Myeloid, Acute/drug therapy*;
Myelodysplastic Syndromes/drug therapy*;
T-Lymphocytes, Regulatory;
Treatment Outcome
- From:
Journal of Experimental Hematology
2022;30(1):36-42
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate regulatory T cells (Tregs) relative content in peripheral blood and bone marrow of patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) treated with or without decitabine (DAC), analyze the immunomodulatory of Tregs in pathogenesis and remission of MDS and AML, as well as effect of DAC on Tregs.
METHODS:From October 2018 to February 2019, 15 patients with MDS and 49 patients with AML (newly diagnosed, treated with DAC or other chemotherapy regimens) were enrolled in this study, and 14 cases with iron deficiency or megaloblastic anemia while without malignant tumor and autoimmune disease as controls. The Tregs relative contents in bone marrow and peripheral blood were analyzed by flow cytometry, meanwhile clinical data of the objects were collected.
RESULTS:In peripheral blood and bone marrow of the patients with MDS and AML, the Tregs relative contents at newly diagnosed were higher than those of the control group (P=0.05, P=0.043). The Tregs relative content of AML patients in DAC regimen treatment group was significantly lower than that in the newly diagnosed group and non-DAC chemotherapy group (P<0.05). In DAC regimen treatment group, the Tregs relative contents was significantly lower in remission group than in non-remission group (P<0.05). There was no difference between DAC regimen treatment group and control group in Tregs relative content.
CONCLUSION:DAC may increase the body's anti-tumor immunity by consuming Tregs content, enhance the body's immune function to identify and kill tumor cells, thereby promote the patients' reliefs.
